Calibrant will identify proteins and protein networks involved in ovarian and breast cancer, as well as select novel therapeutic targets found to be central to disease progression.
Fattaneh Tavasolli, Calibrant’s collaborator at the Yale University School of Medicine, said: “This partnership is enabling effective identification of disease-relevant pathways and drug targets by applying Calibrant’s Gemini platform to targeted discovery from selected cancer cells.”